银屑病患者中趋化素与皮损、肥胖、糖脂代谢及炎症因子的相关性

doi:10.3877/cma.j.issn.1674-0785.2022.06.009

目的

分析趋化素（Chemerin）水平与银屑病（PS）患者皮损严重程度、肥胖、糖脂的代谢紊乱、炎症因子的相关性。

方法

选择2019年1月至2020年1月于广西医科大学第一附属医院收治的150例PS患者，根据PS患者是否并发代谢综合征（MS）分为单纯PS组及PSMS组，同期选择于本院查体中心查体的健康人群40例为对照组。测量并记录各组受检者的身高、体重及腰围（WC），计算身体质量指数（BMI）。采用PS面积与严重程度指数（PASI）量表评估2组患者的皮损严重程度。采集所有受检者空腹静脉血5 ml，采用全自动生化分析仪检测血清甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、空腹血糖（FPG），采用放射免疫分析法检测血清空腹胰岛素（Fins）、超敏C反应蛋白（hs-CRP）、白介素6（IL-6），计算胰岛素抵抗指数（HOMA-IR），采用酶联免疫吸附法检测血清趋化素水平。

结果

单纯PS组及PSMS组患者血清趋化素水平明显高于对照组，PSMS组患者血清趋化素水平明显高于单纯PS组（P＜0.01）。单纯PS组及PSMS组患者血清hs-CRP、IL-6水平明显高于对照组，PSMS组患者血清hs-CRP、IL-6水平明显高于单纯PS组（P＜0.01）。单纯PS组及PSMS组患者BMI、WC、TG、TC、LDL-C、Fins及HOMA-IR水平明显高于对照组，PSMS组患者BMI、WC、TG、TC、LDL-C、Fins及HOMA-IR水平明显高于单纯PS组，HDL-C水平明显低于对照组及单纯PS组（P＜0.01）。单纯PS组患者Fins及HOMA-IR水平明显高于对照组，PSMS组患者PASI水平明显高于单纯PS组（P＜0.01）。Pearson线性相关分析得知，趋化素与PASI、BMI、WC、TG、LDL-C、hs-CRP、IL-6均呈明显正相关（P均＜0.05或＜0.01）。进一步以血清趋化素为因变量，将与因变量具有线性关系的PASI、BMI、WC、TG、LDL-C、hs-CRP、IL-6为自变量进行多元逐步回归分析得知，WC、TG、hs-CRP、IL-6对趋化素存在影响（P均＜0.05或＜0.01）。

结论

趋化素参与PS的发生及发展过程，其水平的变化与PS患者的病情严重程度、肥胖、糖脂代谢紊乱及炎症反应存在密切联系，为评估PS病情发展及有效治疗PS提供新的思路。

关键词: 趋化素, 银屑病, 皮损严重程度, 肥胖, 脂的代谢紊乱, 炎症, 相关性

Objective

To analyze the correlation between serum chemerin and the severity of psoriasis (PS), obesity, lipid metabolism disorder, and inflammation in patients with PS.

Methods

One hundred and fifty patients with PS admitted to the First Affiliated Hospital of Guangxi Medical University from January 2019 to January 2020 were divided into either a simple PS group or a PS with metabolic syndrome (MS) group according to whether they were complicated with MS or not. Meanwhile, 40 healthy people who underwent physical examination at our hospital were selected as a control group. Height, weight, and waist circumference (WC) were measured and recorded, and body mass index (BMI) was calculated. PS area and severity index (PASI) was used to evaluate the severity of lesions in the two groups. Fasting venous blood (5 ml) was collected from all subjects. Serum triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and fasting blood glucose (FPG) were detected using an automatic biochemical analyzer. Serum fasting insulin (FINS), high sensitivity C-reactive protein (hs-CRP), and interleukin-6 were detected by radioimmunoassay. Insulin resistance index (HOMA-IR) was calculated. Serum chemerin level was detected by enzyme-linked immunosorbent assay.

Results

Serum chemerin level was significantly higher in the PS group and PS with MS group than in the control group, and in the PS with MS group than in the PS group (P＜0.01). Serum levels of hs CRP and IL-6 were significantly higher in the PS group and PS with MS group than in the control group, and in the PS with MS group than in the PS group (P＜0.01). The levels of BMI, WC, TG, TC, LDL-C, FINS, and HOMA-IR were significantly higher in the PS group and PSMS group than in the control group, and in the PS with MS group than in the PS group. The level of HDL-C was significantly lower in the PS with MS group than in the PS group and control group (P＜0.01). The levels of FINS and HOMA-IR in the PS group were significantly higher than those in the control group, and PASI in the PSMS group was significantly higher than that in the PS group (P＜0.01). Pearson linear correlation analysis showed that serum chemerin was positively correlated with PASI, BMI, WC, TG, LDL-C, hs-CRP, and IL-6 (P＜0.05 or ＜0.01). Taking serum chemerin as the dependent variable, PASI, BMI, WC, TG, LDL-C, hs-CRP, and IL-6 (having a linear relationship with the dependent variable) were used as independent variables for multiple stepwise regression analysis. The results showed that WC, TG, hs-CRP, and IL-6 had influence on chemerin (P＜0.05 or ＜0.01).

Conclusion

Chemerin is involved in the occurrence and development of PS. Serum chemerin level is closely related to the severity of PS, obesity, disorder of glucose and lipid metabolism, and inflammatory reaction, which provides a new idea for evaluating the development of PS and effective treatment of PS.

Key words: Chemerin, Psoriasis, Severity of skin lesions, Obesity, Dyslipidemia, Inflammation, Correlation

表1 各组受检者血清趋化素水平比较（

\overset{ˉ}{x}

±s）

组别	例数	趋化素（ng/ml）
对照组	40	63.19±16.58
单纯PS组	59	106.84±23.15^a
PSMS组	51	136.71±22.46^ab
F值		133.112
P值		＜0.001

表1 各组受检者血清趋化素水平比较（

\overset{ˉ}{x}

±s）

组别	例数	趋化素（ng/ml）
对照组	40	63.19±16.58
单纯PS组	59	106.84±23.15^a
PSMS组	51	136.71±22.46^ab
F值		133.112
P值		＜0.001

表2 各组受检者血清炎症因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	hs-CRP（mg/L）	IL-6（ng/L）
对照组	40	0.56±0.21	2.06±0.68
单纯PS组	59	1.89±0.67^a	3.29±1.25^a
PSMS组	51	3.16±1.26^ab	4.59±1.28^ab
F值		104.364	55.838
P值		＜0.001	＜0.001

表2 各组受检者血清炎症因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	hs-CRP（mg/L）	IL-6（ng/L）
对照组	40	0.56±0.21	2.06±0.68
单纯PS组	59	1.89±0.67^a	3.29±1.25^a
PSMS组	51	3.16±1.26^ab	4.59±1.28^ab
F值		104.364	55.838
P值		＜0.001	＜0.001

表3 各组受检者肥胖相关因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	BMI（kg/m²）	WC（cm）
对照组	40	22.16±1.89	75.49±7.15
单纯PS组	59	24.68±2.16^a	85.64±8.15^a
PSMS组	51	27.84±2.46^ab	99.84±7.16^ab
F值		76.237	120.004
P值		＜0.001	＜0.001

表3 各组受检者肥胖相关因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	BMI（kg/m²）	WC（cm）
对照组	40	22.16±1.89	75.49±7.15
单纯PS组	59	24.68±2.16^a	85.64±8.15^a
PSMS组	51	27.84±2.46^ab	99.84±7.16^ab
F值		76.237	120.004
P值		＜0.001	＜0.001

表4 各组受检者脂代谢因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	TG（mmol/L）	TC（mmol/L）	LDL-C（mmol/L）	HDL-C（mmol/L）
对照组	40	1.16±0.24	2.61±0.84	1.74±0.42	1.45±0.26
单纯PS组	59	1.56±0.69^a	3.46±0.87^a	2.49±0.58^a	1.35±0.25^a
PSMS组	51	2.86±1.45^ab	5.21±1.93^ab	4.06±0.85^ab	1.06±0.24^ab
F值		41.232	46.998	154.601	31.465
P值		＜0.001	＜0.001	＜0.001	＜0.001

表4 各组受检者脂代谢因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	TG（mmol/L）	TC（mmol/L）	LDL-C（mmol/L）	HDL-C（mmol/L）
对照组	40	1.16±0.24	2.61±0.84	1.74±0.42	1.45±0.26
单纯PS组	59	1.56±0.69^a	3.46±0.87^a	2.49±0.58^a	1.35±0.25^a
PSMS组	51	2.86±1.45^ab	5.21±1.93^ab	4.06±0.85^ab	1.06±0.24^ab
F值		41.232	46.998	154.601	31.465
P值		＜0.001	＜0.001	＜0.001	＜0.001

表5 各组受检者糖代谢因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	FPG	Fins	HOMA-IR
对照组	40	5.12±0.69	11.89±7.15	2.86±1.84
单纯PS组	59	5.29±0.71	15.33±5.46^a	3.58±1.24^a
PSMS组	51	5.78±1.16^ab	19.64±6.78^ab	5.03±2.06^ab
F值		7.154	16.797	19.405
P值		＜0.001	＜0.001	＜0.001

表5 各组受检者糖代谢因子水平比较（

\overset{ˉ}{x}

±s）

组别	例数	FPG	Fins	HOMA-IR
对照组	40	5.12±0.69	11.89±7.15	2.86±1.84
单纯PS组	59	5.29±0.71	15.33±5.46^a	3.58±1.24^a
PSMS组	51	5.78±1.16^ab	19.64±6.78^ab	5.03±2.06^ab
F值		7.154	16.797	19.405
P值		＜0.001	＜0.001	＜0.001

表6 各组受检者PASI水平比较（

\overset{ˉ}{x}

±s）

分组	例数	PASI
单纯PS组	59	14.52±7.46
PSMS组	51	19.36±7.84^a
t值		3.314
P值		0.001

表6 各组受检者PASI水平比较（

\overset{ˉ}{x}

±s）

分组	例数	PASI
单纯PS组	59	14.52±7.46
PSMS组	51	19.36±7.84^a
t值		3.314
P值		0.001

表7 趋化素与各因子相关性分析

指标	趋化素
指标	r值	P值
PASI	0.365	0.027
BMI	0.398	0.041
WC	0.546	0.017
TG	0.387	0.006
TC	0.269	0.247
LDL-C	0.471	0.045
HDL-C	-0.518	0.849
HOMA-IR	0.369	0.516
hs-CRP	0.441	0.025
IL-6	0.385	0.001

表7 趋化素与各因子相关性分析

指标	趋化素
指标	r值	P值
PASI	0.365	0.027
BMI	0.398	0.041
WC	0.546	0.017
TG	0.387	0.006
TC	0.269	0.247
LDL-C	0.471	0.045
HDL-C	-0.518	0.849
HOMA-IR	0.369	0.516
hs-CRP	0.441	0.025
IL-6	0.385	0.001

表8 趋化素与各因子多元线性回归分析

指标	趋化素
指标	β值	r值	P值
PASI	0.158	0.365	0.127
BMI	-0.089	-0.081	0.416
WC	0.225	2.016	0.045
TG	0.256	2.389	0.011
LDL-C	0.089	1.054	0.316
hs-CRP	0.306	3.445	0.005
IL-6	0.356	3.894	0.001

表8 趋化素与各因子多元线性回归分析

指标	趋化素
指标	β值	r值	P值
PASI	0.158	0.365	0.127
BMI	-0.089	-0.081	0.416
WC	0.225	2.016	0.045
TG	0.256	2.389	0.011
LDL-C	0.089	1.054	0.316
hs-CRP	0.306	3.445	0.005
IL-6	0.356	3.894	0.001

1	Danijela M , Slavenka J, Sonja V, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study [J]. An Bras Dermatol, 2017, 92(1): 46-51.
2	Amin M, Darji K, No DJ, et al. Review of phase Ⅲ trial data on IL-23 Inhibitors Tildrakizumab and Guselkumab for psoriasis [J]. J Eur Acad Dermatol Venereol, 2017, 31(10): 1627-1632.
3	Imafuku S, Nakano A, Dakeshita H, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan [J]. J Dermatolog Treat, 2018, 29(1): 24-31
4	Zylla S, Pietzner M, Kühn JP, et al. Serum chemerin is associated with inflammatory and metabolic parameters-results of a population‐based study [J]. Obesity, 2017, 25(2): 468-475.
5	Tümmler C, Snapkov I, Wickström M, et al. Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo [J]. Oncotarget, 2017, 8(56): 95135-95151.
6	Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2017, 389(10068): 528-537.
7	闫丽丽, 吕骥, 贾红玉, 等. 血清chemerin水平与2型糖尿病、非酒精性脂肪性肝病的关系 [J]. 肝脏, 2018, 23(3): 239-241.
8	Gisela H, W QF. Chemerin: a multifaceted adipokine involved in metabolic disorders [J]. J Endocrinol, 2018, 238(2): R79-R94.
9	Yang X, Quan X, Lan Y, et al. Serum chemerin level during the first trimester of pregnancy and the risk of gestational diabetes mellitus [J]. Gynecol Endocrinol, 2017, 33(10): 770-773.
10	易玉芳, 陈春莲. 非酒精性脂肪肝病合并胰岛素抵抗患者血清chemerin和hs-CRP水平的研究 [J]. 重庆医学, 2017, 46(2): 172-174.
11	Aursulesei V, Anisie E, Alecsa AM, et al. Circulating chemerin is associated with subclinical atherosclerosis in obesity [J]. Revista de Chimie Bucharest Original Edition, 2017, 68(3): 541-544.
12	Kennedy AJ , Davenport AP, Ohlstein EH. International union of basic and clinical pharmacology CIII: Chemerin receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) nomenclature, pharmacology, and function [J]. Pharmacol Rev, 2018, 70(1): 174-196.
13	何淑寅, 裴颖皓, 吕海, 等. 血必净注射液对肥胖重症胰腺炎患者血清脂肪因子chemerin和抗炎/促炎系统的影响 [J]. 现代中西医结合杂志, 2018, 27(1): 61-64.
14	阙朝锦, 简守勇. 糖尿病患者血清脂肪因子Chemerin水平改变与临床预后的相关性研究 [J]. 现代仪器与医疗, 2017, 23(4): 70-72.
15	Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence [J]. Arch Dermatol Res, 2017, 309(3): 225-228.
16	Dimitriadis GK, Kaur J, Adya R, et al. Chemerin induces endothelial cell inflammation: activation of nuclear factor-kappa beta and monocyte-endothelial adhesion [J]. Oncotarget, 2018, 9(24): 16678-16690.
17	闫继东, 董洪超, 吕铮, 等. 血清Chemerin、T淋巴细胞亚群基线水平与肺癌预后关系的巢式病例对照研究 [J]. 广东医学, 2017, 38(14): 2154-2157.
18	Jialal I. Chemerin levels in metabolic syndrome: a promising biomarker [J]. Arch Physiol Biochem, 2021, 12: 1-3.
19	Zehsaz F, Farhangi N, Ghahramani M. Exercise training lowers serum chemerin concentration in obese children [J]. Sci Sports, 2017, 32(1): 39-45.
20	Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis [J]. Jaad Case Reports, 2017, 3(3): 230-232.
21	Miehle K, Ebert T, Kralisch S, et al. Circulating serum chemerin levels are elevated in lipoely strophy [J]. Clin Endocrinol (Oxf), 2016, 84(6): 932-938.

[1]	王振宇, 张洪美, 荆琳, 何名江, 闫奇. 膝骨关节炎相关炎症因子与血浆代谢物间的因果关系及中介效应[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 467-473.
[2]	赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[3]	张洁, 罗小霞, 余鸿. 系统性免疫炎症指数对急性胰腺炎患者并发器官功能损伤的预测价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 68-71.
[4]	孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[5]	唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[6]	付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[7]	李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[8]	高娟, 徐建庆, 闫芳, 丁盛华, 刘霞. Rutkow、TAPP、TEP 手术治疗单侧腹股沟疝患者的临床疗效及对血清炎症因子水平的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 675-680.
[9]	刘见, 杨晓波, 何均健, 等. 应用电钩三孔法腹腔镜袖状胃切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(06): 363-364.
[10]	孙璐, 蒋亚玲, 陈凌君. 布托啡诺对脑缺血再灌注损伤大鼠神经炎症和JAK2/STAT3信号通路的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 344-350.
[11]	王涛, 刘静, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗生素耐药背景下中医药防治腹膜透析相关性腹膜炎研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 340-344.
[12]	谢浩文, 丁建英, 刘小霞, 冯毅, 姚婧. 椎旁神经阻滞对微创胃切除肥胖患者术中血流、术后应激及康复质量的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 569-573.
[13]	王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
[14]	陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15]	刘志超, 胡风云, 温春丽. 山西省脑卒中危险因素与地域的相关性分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 424-433.

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	2	0	0	13

来源	本网站	其他网站

次数	14	1
比例	93%	7%

摘要

102

最新录用	在线预览	正式出版

0	0	102

来源	本网站	其他网站

次数	53	49
比例	52%	48%

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between chemokine and skin lesions, obesity, glucose lipid metabolism and inflammatory factors in patients with psoriasis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between chemokine and skin lesions, obesity, glucose lipid metabolism and inflammatory factors in patients with psoriasis